The ASCEND Study is a Phase 3, Multicenter, double-blinded vehicle-controlled study to evaluate the safety and efficacy of topical TMB-001 0.05% ointment for the treatment of RXLI or ARCI Ichthyosis in subjects aged 6 and older.

Total participation time includes approximately 26 weeks to 36 weeks, depending upon your study treatment.

• You will need to visit the study site about 7 times during the study.
• You will be paid for each study visit at the end of participation.

Inclusion Criteria

• Age 6 or older
• Male or non-pregnant, non-lactating females
• Minimum of 10% and maximum of 90% of the total body area involved with Congenital Ichthyosis.

Exclusion Criteria

• Any inflammatory skin diseases that confound the interpretation of results (e.g., atopic dermatitis) unrelated to ichthyosis.
• Used TMB-001 in the past or oral isotretinoin in the past 12 months.
• Subject is immunosuppressed (e.g., human immunodeficiency virus, systemic malignancy, graft (host disease) or receives systemic immunotherapy.

For questions and participant referrals, including self-referrals, contact FDP.researchcenter@northsoundderm.com or call 425-275-4404.